Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galvecta Plus
- Development stage
- Phase 4
- Lead developer
- Clinision
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galvecta Plus is a fixed-dose combination tablet containing vildagliptin and metformin hydrochloride, developed by Clinision for the treatment of type 2 diabetes mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones, which in turn stimulates insulin production and reduces glucagon secretion in a glucose-dependent manner. Metformin is a biguanide that improves glycemic control by decreasing hepatic glucose production and increasing peripheral glucose uptake and utilization. This combination therapy is indicated for patients with type 2 diabetes who are inadequately controlled by diet and exercise alone or by metformin monotherapy.
- Brand names
- Galvecta Plus
- Other names
- metformin + vildagliptinvildagliptin + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on Galvecta Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galvecta Plus.